TREM2 and non-small cell lung carcinoma: One of the leading therapeutic candidates is PY314, a humanized anti-TREM2 monoclonal antibody developed by Pionyr Immunotherapeutics, which is currently being evaluated in a Phase I clinical trial (NCT04691375) in patients with advanced solid tumors, including non-small cell lung cancer (NSCLC), renal cell carcinoma, and colorectal cancer.